TORONTO, Feb. 14, 2018 (GLOBE NEWSWIRE) — WeedMD Inc. (TSX-V:WMD) (OTC:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical cannabis, is pleased to announce that it has joined the world-renown Cannabis Database Project led by the Technion-Israel Institute of Technology. Together, they will be collaborating in the research of cannabinoid and terpenoid profiles of 25 of WeedMD’s cannabis strains. This data will be added to an international database that correlates pharmacological effects used to determine the most effective cannabis treatments – strains, dose, and route of administration – for clinical purposes. This is just the first of multiple research and development initiatives WeedMD is embarking on, and plans to announce, as the Company further develops its medical cannabis offering for both the domestic and global medical cannabis markets.
“We are proud to be at the forefront of investing in cannabis research, awareness and